It is currently Tue Jul 29, 2014 3:59 am

News News of ThisIsMS

Site map of ThisIsMS » Forum : ThisIsMS

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

Environmental factors, Australia Research

There is convincing evidence that environmental factors are contributing to the rise in autoimmune diseases like Multiple Sclerosis, Crohn’s disease and Type 1 diabetes around the world. A study coordinated at ANU is set to discover what some of these factors might be.

Teams of medical scientists worldwide are searching for cures for autoimmune diseases like Type 1 diabetes, Multiple Sclerosis and Crohn’s disease. While this worthy activity progresses, there is a quiet anticipation elsewhere ...
Read more : Environmental factors, Australia Research | Views : 1147 | Replies : 1 | Forum : General Discussion




IL23

Archemix Announces Strategic Alliance With Elan to Discover and Develop Aptamer Therapeutics

Archemix Corp. announced today a multi-year, multi-product alliance with Elan Corporation plc focused on the discovery, development, and commercialisation of first-in-class aptamer therapeutics to treat autoimmune disease. The companies will seek to develop aptamer therapeutics to IL-23, a cytokine that has emerged as a mediator in the chronic autoimmune inflammatory diseases, and additional protein targets. The collaboration combines Archemix's extensive expertise in aptamer ...
Read more : IL23 | Views : 797 | Replies : 0 | Forum : General Discussion


Silk

Another technology story. Perhaps they will repair us with silk and micro-chips in the future.

http://news.bbc.co.uk/1/hi/sci/tech/5172422.stm
Read more : Silk | Views : 840 | Replies : 0 | Forum : General Discussion


Overwhelming

Wow..
For a newbie, this is so overhwelming..... :cry:
Read more : Overwhelming | Views : 2729 | Replies : 4 | Forum : Tysabri (Antegren or Natalizumab)




Brain chip

MS news is thin on the ground and August / September are quiet months before the ECTRIMS and ACRIMS (Oct) conferences take place and new research / trial results are released.

Technological advances continue - the BBC website reported today that scientists were developing a retina which could be attached to the optic nerves and give people back their site (probably within ten years). Another advance reported today was a brain chip which would help ...
Read more : Brain chip | Views : 910 | Replies : 0 | Forum : General Discussion


Update: you may or may not know

I spoke with our DR about setting up appt on infusion. The DR in Memphis is awaiting training to be certified. I call the 800# for financial assistance, just getting everything ready. Was told that Tysabri is not commercially available yet, but will be most likely this month. They are awaiting approval from the FDA on training materials for the infusion sites so they can turn around and certify them. Looks like last of July ...
Read more : Update: you may or may not know | Views : 1528 | Replies : 1 | Forum : Tysabri (Antegren or Natalizumab)


newest thing to happen to me

okay everyone could some one please explain to me why this stuff is going on..i hate the fact that i cant get a answer to anything..i woke up monday morning at around 12 or so and my whole right size was seizing up on me..i had to call 911 very scary..took me in and did more mris and guess what nothing on them at all...AGAIN......i was laughing and crying at the same time..the poor dr ...
Read more : newest thing to happen to me | Views : 1385 | Replies : 9 | Forum : General Discussion


Campath trials

Genzyme's second quarter results were published today and included the following about Campath:

Preparations are underway for the initiation of a phase 3 study of
alemtuzumab (Campath) for the treatment of relapsing/remitting multiple
sclerosis, which is expected during the second half of this year. In
addition, nearly all participating patients have now completed at least
24 months in the ongoing Phase 2 clinical trial comparing alemtuzumab
with Rebif(R) (interferon beta-1a) for the treatment of multiple ...
Read more : Campath trials | Views : 1291 | Replies : 0 | Forum : Drug Pipeline


 

Login  •  Register


Statistics

Total posts 218745 • Total topics 22546 • Total members 14192